The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system – a first in the pharma industry.
Research finds tumor-promoting potential in common skin fungus
A common skin fungus, Malassezia globosa may invade deep tissues through the skin or by other means, then cause tumor growth, according to a new
September 5, 2024